Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
तुलना करने के लिए मीट्रिक्स | KZR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधKZRपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.4x | −2.1x | −0.5x | |
PEG अनुपात | −0.02 | 0.00 | 0.00 | |
क़ीमत/बुक | 0.3x | 2.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 25.9x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 204.1% | 199.4% | 48.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | −4.1% | 9.2% | अनलॉक करें |